FI20022159A0 - Uusia farmaseuttisia yhdisteitä - Google Patents

Uusia farmaseuttisia yhdisteitä

Info

Publication number
FI20022159A0
FI20022159A0 FI20022159A FI20022159A FI20022159A0 FI 20022159 A0 FI20022159 A0 FI 20022159A0 FI 20022159 A FI20022159 A FI 20022159A FI 20022159 A FI20022159 A FI 20022159A FI 20022159 A0 FI20022159 A0 FI 20022159A0
Authority
FI
Finland
Prior art keywords
unsubstituted
substituted
prodrug forms
methods
pharmaceutical compounds
Prior art date
Application number
FI20022159A
Other languages
English (en)
Swedish (sv)
Inventor
Tomi Jaervinen
Riku Niemi
Juhani Huuskonen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Priority to FI20022159A priority Critical patent/FI20022159A0/fi
Publication of FI20022159A0 publication Critical patent/FI20022159A0/fi
Priority to DE60304741T priority patent/DE60304741T2/de
Priority to SI200330300T priority patent/SI1572198T1/sl
Priority to CA2508335A priority patent/CA2508335C/en
Priority to ES03812203T priority patent/ES2262031T3/es
Priority to JP2004556387A priority patent/JP4667042B2/ja
Priority to MEP-2008-864A priority patent/ME00521B/me
Priority to EP03812203A priority patent/EP1572198B1/en
Priority to PCT/FI2003/000933 priority patent/WO2004050635A2/en
Priority to EA200500922A priority patent/EA008251B1/ru
Priority to DK03812203T priority patent/DK1572198T3/da
Priority to KR1020057009983A priority patent/KR20050114603A/ko
Priority to YU20050428A priority patent/RS52571B/en
Priority to CNB2003801051320A priority patent/CN100560070C/zh
Priority to AT03812203T priority patent/ATE323484T1/de
Priority to BR0317024-1A priority patent/BR0317024A/pt
Priority to AU2003302622A priority patent/AU2003302622B2/en
Priority to NZ540466A priority patent/NZ540466A/en
Priority to PL377530A priority patent/PL216530B1/pl
Priority to MXPA05005963A priority patent/MXPA05005963A/es
Priority to US10/537,622 priority patent/US7759496B2/en
Priority to PT03812203T priority patent/PT1572198E/pt
Priority to IL168882A priority patent/IL168882A/en
Priority to ZA200504533A priority patent/ZA200504533B/en
Priority to IS7911A priority patent/IS2282B/is
Priority to HRP20050617AA priority patent/HRP20050617B1/hr
Priority to NO20053302A priority patent/NO330392B1/no
Priority to CY20061100913T priority patent/CY1105699T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
FI20022159A 2002-12-05 2002-12-05 Uusia farmaseuttisia yhdisteitä FI20022159A0 (fi)

Priority Applications (28)

Application Number Priority Date Filing Date Title
FI20022159A FI20022159A0 (fi) 2002-12-05 2002-12-05 Uusia farmaseuttisia yhdisteitä
PT03812203T PT1572198E (pt) 2002-12-05 2003-12-05 Novos compostos farmaceuticos com actividade de receptor alfa2.
YU20050428A RS52571B (en) 2002-12-05 2003-12-05 IMIDAZOLE DERIVATIVES WITH AFFINITY AFTER THE ACTIVITY OF ALPHA 2 RECEPTORS
AT03812203T ATE323484T1 (de) 2002-12-05 2003-12-05 Neue pharmazeutische verbindungen mit alpha2receptor aktivität
CA2508335A CA2508335C (en) 2002-12-05 2003-12-05 Imidazole derivatives having affinity for alpha 2 receptors activity
ES03812203T ES2262031T3 (es) 2002-12-05 2003-12-05 Nuevos compuestos farmaceuticos con actividad receptora alpha2.
JP2004556387A JP4667042B2 (ja) 2002-12-05 2003-12-05 新規医薬化合物
MEP-2008-864A ME00521B (me) 2002-12-05 2003-12-05 Derivati imidazola sa afinitetom prema aktivnosti alfa 2 receptora
EP03812203A EP1572198B1 (en) 2002-12-05 2003-12-05 New pharmaceutical compounds with alpha2receptor activity
PCT/FI2003/000933 WO2004050635A2 (en) 2002-12-05 2003-12-05 Imidazol derivatives having affinity for alpha 2 receptors activity
EA200500922A EA008251B1 (ru) 2002-12-05 2003-12-05 Производные имидазола, обладающие аффиностью по отношению к альфарецепторам
DK03812203T DK1572198T3 (da) 2002-12-05 2003-12-05 Farmaceutiske forbindelser med alfa2-receptoraktivitet
KR1020057009983A KR20050114603A (ko) 2002-12-05 2003-12-05 신규 약학적 화합물
DE60304741T DE60304741T2 (de) 2002-12-05 2003-12-05 Neue pharmazeutische verbindungen mit alpha2receptor aktivität
CNB2003801051320A CN100560070C (zh) 2002-12-05 2003-12-05 具有α2受体亲和活性的咪唑衍生物
SI200330300T SI1572198T1 (sl) 2002-12-05 2003-12-05 Nove farmacevtske spojine z alfa2 receptorsko aktivnostjo
BR0317024-1A BR0317024A (pt) 2002-12-05 2003-12-05 Derivados de imidazol que têm afinidade pela atividade dos receptores alfa 2
AU2003302622A AU2003302622B2 (en) 2002-12-05 2003-12-05 Imidazol derivatives having affinity for alpha 2 receptors activity
NZ540466A NZ540466A (en) 2002-12-05 2003-12-05 Imidazole derivatives having affinity for alpha 2 receptors activity
PL377530A PL216530B1 (pl) 2002-12-05 2003-12-05 Estry alkilowe 4-(6-hydroksyindan-1-ylometylo)-1H-imidazolu, ich zastosowanie oraz zawierające je kompozycje farmaceutyczne
MXPA05005963A MXPA05005963A (es) 2002-12-05 2003-12-05 Derivados de imidazol que tienen afinidad hacia la actividad de los receptores alfa-2.
US10/537,622 US7759496B2 (en) 2002-12-05 2003-12-05 Imidazole derivatives having affinity for alpha 2 receptors activity
IL168882A IL168882A (en) 2002-12-05 2005-05-30 Imidazole derivatives having affinity for alpha 2 receptor activity
ZA200504533A ZA200504533B (en) 2002-12-05 2005-06-02 Imidazol derivatives having affinity for alpha 2 receptors activity.
IS7911A IS2282B (is) 2002-12-05 2005-06-23 Ný lyfefnasambönd með alfa2viðtakavirkni
HRP20050617AA HRP20050617B1 (hr) 2002-12-05 2005-07-04 Derivati imidazola s afinitetom prema aktivnosti alfa 2 receptora
NO20053302A NO330392B1 (no) 2002-12-05 2005-07-05 Imidazolderivater med affinitet for alfa 2-reseptoraktivitet og anvendelser derav, samt farmasoytisk preparat omfattende imidazolderivat
CY20061100913T CY1105699T1 (el) 2002-12-05 2006-07-03 Νεες φαρμακευτικες ενωσεις με αλφα2υποδοχεα δραστηριοτητας

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20022159A FI20022159A0 (fi) 2002-12-05 2002-12-05 Uusia farmaseuttisia yhdisteitä

Publications (1)

Publication Number Publication Date
FI20022159A0 true FI20022159A0 (fi) 2002-12-05

Family

ID=8565048

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20022159A FI20022159A0 (fi) 2002-12-05 2002-12-05 Uusia farmaseuttisia yhdisteitä

Country Status (27)

Country Link
US (1) US7759496B2 (fi)
EP (1) EP1572198B1 (fi)
JP (1) JP4667042B2 (fi)
KR (1) KR20050114603A (fi)
CN (1) CN100560070C (fi)
AT (1) ATE323484T1 (fi)
BR (1) BR0317024A (fi)
CA (1) CA2508335C (fi)
CY (1) CY1105699T1 (fi)
DE (1) DE60304741T2 (fi)
DK (1) DK1572198T3 (fi)
EA (1) EA008251B1 (fi)
ES (1) ES2262031T3 (fi)
FI (1) FI20022159A0 (fi)
HR (1) HRP20050617B1 (fi)
IL (1) IL168882A (fi)
IS (1) IS2282B (fi)
ME (1) ME00521B (fi)
MX (1) MXPA05005963A (fi)
NO (1) NO330392B1 (fi)
NZ (1) NZ540466A (fi)
PL (1) PL216530B1 (fi)
PT (1) PT1572198E (fi)
RS (1) RS52571B (fi)
SI (1) SI1572198T1 (fi)
WO (1) WO2004050635A2 (fi)
ZA (1) ZA200504533B (fi)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070093477A1 (en) 2005-08-25 2007-04-26 Schering Corporation And Pharmacopeia Drug Discovery, Inc. Alpha2C adrenoreceptor agonists
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
US8324213B2 (en) 2008-10-07 2012-12-04 Merck Sharp & Dohme Corp. Biaryl-spiroaminooxazoline analogues as alpha 2C adrenergic receptor modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673679A (en) * 1986-05-14 1987-06-16 E. I. Du Pont De Nemours And Company Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
SK3812001A3 (en) 1998-09-28 2002-02-05 Orion Corp Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal, intrathecal or epidural administration
NZ518447A (en) * 1999-10-29 2004-10-29 Orion Corp Treatment or prevention of hypotension and shock
US6388090B2 (en) * 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
FI20000073A0 (fi) 2000-01-14 2000-01-14 Orion Yhtymae Oy Uusia imidatsolijohdannaisia
US7091232B2 (en) 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7439268B2 (en) * 2003-07-18 2008-10-21 Idexx Laboratories Compositions containing prodrugs of florfenicol and methods of use

Also Published As

Publication number Publication date
ATE323484T1 (de) 2006-05-15
MXPA05005963A (es) 2005-08-18
CN100560070C (zh) 2009-11-18
RS20050428A (en) 2007-08-03
WO2004050635A3 (en) 2004-09-02
HRP20050617B1 (hr) 2013-07-31
NO20053302L (no) 2005-07-05
CN1735409A (zh) 2006-02-15
CA2508335C (en) 2011-09-13
IS7911A (is) 2005-06-23
NZ540466A (en) 2008-04-30
JP4667042B2 (ja) 2011-04-06
BR0317024A (pt) 2005-10-25
AU2003302622A1 (en) 2004-06-23
ZA200504533B (en) 2006-03-29
EA008251B1 (ru) 2007-04-27
RS52571B (en) 2013-04-30
CY1105699T1 (el) 2010-12-22
CA2508335A1 (en) 2004-06-17
PT1572198E (pt) 2006-08-31
WO2004050635A2 (en) 2004-06-17
US7759496B2 (en) 2010-07-20
DK1572198T3 (da) 2006-07-03
DE60304741D1 (de) 2006-05-24
NO20053302D0 (no) 2005-07-05
ME00521B (me) 2011-10-10
EA200500922A1 (ru) 2005-12-29
DE60304741T2 (de) 2007-04-12
US20060178417A1 (en) 2006-08-10
NO330392B1 (no) 2011-04-04
PL216530B1 (pl) 2014-04-30
KR20050114603A (ko) 2005-12-06
EP1572198A2 (en) 2005-09-14
IL168882A (en) 2010-05-31
SI1572198T1 (sl) 2006-08-31
ES2262031T3 (es) 2006-11-16
PL377530A1 (pl) 2006-02-06
HRP20050617A2 (en) 2005-10-31
JP2006509780A (ja) 2006-03-23
EP1572198B1 (en) 2006-04-19
IS2282B (is) 2007-09-15

Similar Documents

Publication Publication Date Title
ATE556058T1 (de) 1-(2h)-isochinolonderivat
DK1261602T3 (da) Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer
NO20062269L (no) Pyridin-karboksylsyrederivater som glucokinasemodulatorer
DE60315265D1 (de) Stickstoffhaltige heterocyclische verbindung und arzneimittel davon
AR019263A1 (es) Compuestos derivados de hidroxamida del acido (4-arilsulfonilamino) tetrahidropiran-4-carboxilico, composiciones farmaceuticas y metodos de tratamiento.
WO2008114819A1 (ja) 新規アデニン化合物
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
DK1178967T3 (da) Quinolinderivater som inhibitorer af MEK-enzymer
IL161559A0 (en) Dibenzylamine derivatives and pharmaceutical compositions containing the same
ME00981B (me) 1,2,4,5-tetrahidr0-3h-benzazepinska jedinjenja, postupak za njihovu izradu i smješe koje ih sadrže
AU2001235838A1 (en) Imidazol derivatives as raf kinase inhibitors
NO20054092L (no) Nye tricykliske azepinforbindelser, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
IS2282B (is) Ný lyfefnasambönd með alfa2viðtakavirkni
WO2004091627A3 (en) Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
EA200600551A1 (ru) Соединения пиперазина, способ их получения и фармацевтические композиции, которые их содержат
RS54061B1 (en) QUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONCERNING THEM, AND THEIR APPLICATIONS
MY134226A (en) 1,2-dihydropyrazol-3-ones which control inflammatory cyctokines
EA200001248A1 (ru) Новые линейные и циклические производные мочевины, способ их получения и их содержащие фармацевтические композиции
EA200500028A1 (ru) Новые соединения 3-(4-оксо-4h-хромен-2-ил)-(1h)-хинолин-4-она, способ их получения и фармацевтические композиции, которые их содержат
ATE401884T1 (de) Arzneizusammensetzungen enthaltend oxapenem-3- carbonsäuren
NO20022891L (no) Nye cykliske <alfa>-amino-<gamma>-hydroksyamidforbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetningerinneholdende dem
HRPK20070123B3 (en) Phenyl-piperazine derivatives as serotonin reuptake inhibitors
ATE268769T1 (de) Pyrimidinderivate mit antitumor-wirkung
ECSP993005A (es) Compuestos de sulfonilbenceno como agentes anti-inflamatorios / analgesicos
EA200200636A1 (ru) Новые соединения 3-имино-1,2-дитиола, способ их получения и фармацевтические композиции, их содержащие